You are here

Article Text

Article menu
Download PDFPDF
Industry watch
RJ Reynolds has not published a negative randomised clinical trial of Camel Snus for smoking cessation
  1. Eunice E Neeley1,
  2. Stanton A Glantz1,2
  1. 1Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, California, USA
  2. 2Department of Medicine, University of California, San Francisco, San Francisco, California, USA
  1. Correspondence to Professor Stanton A Glantz, Center for Tobacco Control Research and Education, University of California, San Francisco, Room 366 Library, 530 Parnassus Avenue, San Francisco, CA 94143-1390, USA; glantz{at}medicine.ucsf.edu

https://doi.org/10.1136/tobaccocontrol-2016-052913

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In 2009, RJ Reynolds Tobacco (RJR) created ‘The Smoker Cessation/Migration Study’, a randomised control trial, to compare Camel Snus to Nicorette nicotine replacement therapy (NRT) for smoking cessation over 1 year. RJR also examined the effect of providing information on the health benefits of switching from cigarettes to smokeless tobacco (ST).1 ,2

    RJR's clinical studies division,3 together with legal, financial, marketing and innovation teams,4 created the earliest protocols.

    The study had three arms, with 200 smokers in each: (1) Camel Snus with one-time relative risk ST information; (2) Camel Snus without ST information; and (3) Nicorette lozenges. All participants were given study products for 12 weeks to aid with smoking cessation.5 Biochemically-verified cigarette …

    View Full Text

    Footnotes

    • Contributors SAG developed the idea for the study. EEN collected the data and drafted the paper. Both authors revised the paper and approved it for submission.

    • Funding This work was funded by National Cancer Institute Grant CA-087472.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement All the data used in this study are publicly available documents.